Background
==========

Cardiovascular disease remains to be the most unexceptional cause of morbidity over the past few years in spite of the usage of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) that lower low-density lipoprotein (LDL) cholesterol \[[@B1]\]. Elevated LDL or lowered high-density lipoprotein (HDL) cholesterol level is a crucial risk factor for cardiovascular ailments \[[@B2],[@B3]\]. Accordingly, raising HDL induced by cholesteryl ester transfer protein (CETP) inhibition is an attractive tactic for anti-atherosclerosis, which may reduce the residual risk of cardiovascular events \[[@B4]\].

Torcetrapib (Figure [1](#F1){ref-type="fig"}), a CETP inhibitor firstly proposed by Pfizer Inc., had been characterized to suppress the exchange of HDL and triglyceride-rich lipoprotein in patients with hyperlipidemia, which resulted in the elevation of HDL in the peripheral circulatory system \[[@B5]\]. However, torcetrapib was found to be associated with incremental mortality and cardiovascular event risk, including activated aldosterone system and induced hypertension in the ILLUMINATE trial \[[@B6]\]. Off-target effects occurred via inhibition of a kinase not intended to be targets for drugs. So far, the detailed mechanisms underlying the off-target adverse effects of torcetrapib are quite limited and remain obscure.

![**Chemical structure of torcetrapib.** ChemSpider (<http://www.chemspider.com/>) ID: 140123; Molecular Formula: C~26~H~25~F~9~N~2~O~4~; Average mass: 600.473328 Da; Systematic name: Ethyl(2R,4S)-4-{\[3,5-bis(trifluoromethyl)benzyl\](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-1(2H)-quinolinecarboxylate.](1752-0509-6-152-1){#F1}

With the rapid development of high-throughput screen (HTS) technology such as microarray, the superiority of systems biology and network pharmacology gradually embodied \[[@B7],[@B8]\]. Reconstructing networks of biological organism through integrating diverse sources are crucial for comprehending biological processes associated with pathema. Computational biology provides profitable patronage to address the scientific suspense through pragmatic modeling and theoretical exploration, which furnish a brand-new network poly-pharmacology approach for drug identification and discovery \[[@B9]\]. Based on systems biology, it affords a rewarding assistance to improve drug potency and forecast the unwanted off-target effects at a higher efficiency and lower attrition, especially for a new generation of known drugs \[[@B10]\]. In addition, as a crucial technology in drug discovery, reverse docking approach also revealed a prominent performance in understanding the basis of a drug and receptors which provided benignant avails in drug target identification \[[@B11]\].

To better expound the unfavorable adverse reactions of torcetrapib, a novel network systems approach was proposed by integrating high quality manually curated data with microarray gene expression profiling into a context-specific network, which allowed us to explicate the off-target adverse effects of torcetrapib in a different angle. Detailed illustrations are as follows.

Results and discussion
======================

Although statins had been well characterized as the best studied contemporary cardiovascular therapies over the past few years, the optimal approach to LDL reduction remained to be controversial. Meanwhile, the prejudice of low levels of HDL cholesterol in cardiovascular system became increasingly prominent, which had a tight consanguinity with myocardial infarction and death from coronary heart disease (CHD). Thus, strategies targeting HDL had been a therapeutic tactic for anti-atherosclerosis. As a novel CETP inhibitor, torcetrapib had been recognized as one of the auspicious foremost candidates for elevating HDL. However, owing to its high risk of mortality, torcetrapib experienced the battle of "Waterloo", which overshadowed the entire prospect of anti-cholesterol drugs.

With the speedy development of bioinformatics, organization of knowledge on drug, disease and target inaugurated a brand-new era in drug target identification and discovery. Network pharmacology comprehended the complexity of biological processes by integrating network biology and poly-pharmacological perspective to create predictive models \[[@B12]\]. Network reconstruction and integration of aberrant genes involved in drugs could uncover the capital gene regulatory networks (GRNs) modules which led to the dysfunction of regular biological systems.

After integrating HPRD (Human Protein Reference Database, <http://www.hprd.org/>) with a manually curated human signaling network acquired from Cui et al. \[[@B13]\], the over-expressed microarray data originated from human adrenal carcinoma cells treated with torcetrapib were mapped to construct the context-specific network. Cytoscape (<http://www.cytoscape.org/>), an open source package for visualizing complex networks and integrating diverse types of resources, is an indispensable platform for bioinformatics, social network analysis and network pharmacology \[[@B14]\]. The drug-gene interaction network of torcetrapib was established utilizing three plugins, including BisoGenet \[[@B15]\], NetworkAnalyzer and ClusterONE \[[@B16]\]. Molecular relations (protein-protein and protein/DNA interactions) were connected based on SysBiomics platform (<http://biomine.cigb.edu.cu/sysbiomics/>). GRNs communities, which reflected the situation of torcetrapib-associated over-expressed genes, were detected in MCODE algorithm. The DAVID functional annotation tool (<http://david.abcc.ncifcrf.gov/>) \[[@B17],[@B18]\] and ToppFun web server (<http://toppgene.cchmc.org/enrichment.jsp>) \[[@B19]\] were employed freely to identify the significantly-represented biological processes and the enriched signaling pathways, respectively.

An *in silico* drug target reverse searching method was applied for screening potential off-targets of torcetrapib. Reverse docking, a flexible ligand-receptors inverse docking program, conducted computer-automated search of potential targets of a small molecule by docking it to a cavity of each receptor. To optimize docking parameter, an accurate docking module in Discovery Studio (version 2.5, Accelrys) named CDOCKER was employed. The cavity of each protein was derived from the three dimensional structures of Protein Data Bank (PDB, <http://www.rcsb.org/>) based on the enriched pathways. Proteins with high binding affinity with torcetrapib were considered to be the most potential direct off-targets.

Torcetrapib-associated signaling map construction
-------------------------------------------------

Totally, 388 differentially expressed genes were identified by SAM (Additional file [1](#S1){ref-type="supplementary-material"}). As shown in Figure [2](#F2){ref-type="fig"}, with the assistance of SAM Plot Controller, we draw a band of two parallel lines with a distance of 1.1724 (delta value) according to the False Discovery Rate (FDR) threshold of 0.05. After combining HPRD (Raw data is available in Additional file [2](#S2){ref-type="supplementary-material"}) with a manually curated human signaling network obtained from Cui et al. \[[@B13]\], an integrated human signaling network contained 10503 nodes and 47660 edges were connected on the basis of SysBiomics platform, which amassed miscellaneous data from BIND, HPRD, MINT, DPI, BIOGRID and INTACT \[[@B15]\]. To uncover torcetrapib-associated regulatory network, 215 out of the 388 significantly up-regulated genes were mapped to illustrate the context-specific network.

![**SAM plot sheet output of the gene expression profiling of the microarray dataset from a study of torcetrapib (GEO: GDS3556).** SAM plot sheet illustrated a signature for differentially expressed genes of H295 adrenal carcinoma cells treated with torcetrapib. Red dots represented gene sets up-regulated.](1752-0509-6-152-2){#F2}

GRNs modules excavation
-----------------------

Genes in biological networks always enjoy a similarity in which they are more intimately connected to implement particular biological functions. This kind of dense clique-like structure within a network theme is termed as GRNs modules or gene sets \[[@B20]\]. GRNs, the specific sub-networks that gave rise to the dysfunction of regulator in biological systems, were critical in maintaining the stability of the entire network. Thus, analysis of gene lists regulated by the over-represented microarray genes was propitious to annotate the specific biological processes involved in torcetrapib-associated undesired off-target effects. Currently, we utilized the MCODE algorithm in ClusterONE plugin, which searched nodes for expansion by computing a score of local density for each node in a graph, to detect the dominant controller of gene regulation associated with torcetrapib. Totally, the largest three principal modules (Figure [3](#F3){ref-type="fig"}) encoded by torcetrapib-gene expression profiling (with score above 2.0) were excavated and the complete lists of the core GRNs were presented in Additional file [3](#S3){ref-type="supplementary-material"}.

![**Significant up-regulated torcetrapib signature driving genes (central location) in the gene regulatory networks (GRNs) modules (circle layout).** (**A**) For GRN1. (**B**) For GRN2. (**C**) For GRN3.](1752-0509-6-152-3){#F3}

Gene ontology (GO) analysis
---------------------------

To assess the capital GRNs in biological processes, the DAVID functional annotation tool was utilized \[[@B17],[@B18]\]. Our results for the enriched over-represented biological processes implicated in torcetrapib were presented in Figure [4](#F4){ref-type="fig"} (FDR\<0.01). Of note, most of these functions were highly bound up with cell death, apoptosis, signaling transduction, tyrosine modification and regulation of RNA metabolic process.

![**Heatmap of the over-represented biological processes associated with torcetrapib generated by Cluster/TreeView.** Columns represented significant over-represented biological processes, while rows corresponded to gene regulatory networks (GRNs) modules. Expression values were logarithm of ratio value utilizing log transform data. Red color in each grid represented positive, while white represented null.](1752-0509-6-152-4){#F4}

Pathway enrichment analysis
---------------------------

Pathway, a set of genes that acted together to implement certain biological functions, was an excellent indicator to annotate dysregulation in view of gene regulation. Thus, we speculated the regulated pathways of the momentous gene sets based on ToppFun, a web server for comparative enrichment analysis of multiple gene lists \[[@B19]\]. Significant over-expressed pathways of the capital GRNs were listed in Table [1](#T1){ref-type="table"} (FDR\<0.05). Accordingly, torcetrapib mainly influenced IL-2 Receptor Beta Chain in T cell Activation, Platelet-Derived Growth Factor Receptor (PDGFR) beta signaling pathway, IL2-mediated signaling events, ErbB signaling pathway and signaling events mediated by Hepatocyte Growth Factor Receptor (HGFR, c-Met) via up-regulation of CBL, SOCS1, JAK1, JUN, TGFBR2 and EXOSC6.

###### 

Main enriched signaling pathways of torcetrapib related to its adverse reactions (FDR\<0.05)

  **Index**   **Driving genes**                                   **Pathways**                                                                                 ***p*-value**
  ----------- --------------------------------------------------- -------------------------------------------------------------------------------------------- ---------------
  GRN1        CBL,SOCS1                                           BioCarta: IL-2 Receptor Beta Chain in T cell Activation                                      4.112E-18
  CBL,SOCS1   NCI-Nature Curated: PDGFR-beta signaling pathway    5.309E-12                                                                                    
  SOCS1       NCI-Nature Curated: IL2-mediated signaling events   1.491E-10                                                                                    
  CBL         KEGG pathway: ErbB signaling pathway                1.838E-10                                                                                    
  GRN2        JUN                                                 NCI-Nature Curated: Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)   1.175E-4
  GRN3        EXOSC6                                              Reactome: Genes involved in mRNA Decay by 3' to 5' Exoribonuclease                           4.537E-14
  EXOSC6      Reactome: Genes involved in Metabolism of mRNA      3.187E-8                                                                                     
  EXOSC6      Reactome: Genes involved in Metabolism of RNA       6.834E-6                                                                                     

*FDR*: false discovery rate.

Reverse docking analysis
------------------------

Predicting potential binding receptors of ligands by docking protocol could assist in new targets discovery and identification. Reverse docking approach, the opposite of the direct docking method firstly proposed by Chen et al. \[[@B11]\], could identify probable binding proteins for a specific small molecule. CDOCKER, an accurate docking module in Discovery Studio, is a powerful tool to predict the conformation and related binding energies of ligand-receptor complexes. In the present study, performance was conducted by docking torcetrapib to a series of proteins based on the enriched signaling pathways. Our results for reverse docking targets of torcetrapib were listed in Table [2](#T2){ref-type="table"}.

###### 

Off-targets candidates for torcetrapib identified by reverse docking procedure

  **Rank**      **Target details (PDB Code)**   **Ligand**      **Binding score (kcal/mol)**
  ------------- ------------------------------- --------------- ------------------------------
  1             PDGFR (1GQ5)                    crenolanib      28.7711
  torcetrapib   42.0439                                         
  2             HGFR (3U6H)                     compound 03X    40.8298
  torcetrapib   40.2422                                         
  3             IL-2 receptor (4HCV)            compound 13 J   46.049
  torcetrapib   38.126                                          
  4             ErbB1 (3BEL)                    compound POX    35.5674
  torcetrapib   34.7466                                         

IL2-mediated signaling events and activation of T cell receptor pathway mediated by IL-2 gave rise to the unwanted effects for torcetrapib
------------------------------------------------------------------------------------------------------------------------------------------

Among the myriad of intra-cellular signaling networks that governed the pathogenesis of cardiovascular event, activation of T cell receptor signaling mediated by IL-2 awoke our concern. Recently, numerous evidences illustrated that the pathological proceeding of atherosclerosis had an intimate relation with chronic inflammation \[[@B21]\]. As a primary regulator of immune cell, the characteristics of T cell receptor pathway mediated by IL-2 in atherosclerosis had been certificated \[[@B22]-[@B25]\]. Lipid deposition and infiltration of inflammatory cells were responsible for the formation of atherosclerosis and a variety of cells such as T lymphocytes, monocytes, macrophages, endothelial cells, platelet and vascular smooth muscle cells were engaged in the occurrence and progression of atherosclerosis. Meanwhile, leukocyte adhesion molecules and inflammatory chemokines were other elements which facilitated the accumulation of plaques. T cells activated by IL-2 in the arterial vessel played a momentous function in atherosclerosis, which induced apoptosis of vascular smooth muscle cells and facilitated the formation of plaques \[[@B26]\].

Similarly, hypertension is also considered to be an inflammatory pathema \[[@B27],[@B28]\]. Considerable documents illustrated that T cells could stimulate the release of cytokines and inflammatory factors, which resulted in hypertension and myocardial fibrosis. As a vasoactive peptide, angiotensin II (AngII) was identified as a crucial factor in the development of hypertension. Activated T cells mediated by IL-2 had been authenticated to be rich in AngII receptor, which could promote the migration of dendritic cells \[[@B29]\] and amplify inflammation through autocrine \[[@B30],[@B31]\]. More and more evidences attested the relations between experimental hypertension and T cell immune activation. Guzik et al. \[[@B32]\] found that mice continuously infiltrated with AngII exhibited extraordinary abnormalities of T cell. Further studies disclosed that AngII significantly increased the amount of T cell in the perivascular adipose tissue via enrichment of CD69/CD44 or activation of Chemokines (C-C motif) receptor 5, which subsequently elevated the level of T lymphocytes in the peripheral circulatory system. Thus, the off-target prediction was applied by docking torcetrapib to IL-2 receptor.

The X-ray crystallography of IL-2 receptor with an endogenous ligand (compound 13 J, 3-{4-amino-1-\[(3S)-1-propanoylpiperidin-3-yl\]-1H-pyrazolo\[3,4-d\]pyrimidin-3-yl}-N-\[4- (propan-2-yl)phenyl\]benzamide) was downloaded from PDB (PDB code 4HCV). Compound 13 J (Figure [5A](#F5){ref-type="fig"}), a nonreceptor tyrosine kinase Itk (interleukin-2 inducible T- cell kinase) blocker, exhibited positive activities with IC~50~ 0.4 μM. Figure [5](#F5){ref-type="fig"} showed the results of the calculations. The docking protocol revealed that both compound 13 J and torcetrapib could cage into the IL-2 receptor binding pocket. The interaction energy of torcetrapib and IL-2 receptor complex was decreased compared with compound 13 J (compound 13 J, 46.049 kcal/mol; torcetrapib, 38.126 kcal/mol). Docking consequences elaborated that the conserves amino acid residues LYS391, GLN373 and SER371 in IL-2 receptor played a decisive role in maintaining the functional conformation and directly involved in compound 13 J and torcetrapib binding.

![**Prediction of IL-2 receptor as a possible off-target of torcetrapib.** (**A**) Docked complex of IL-2 receptor (PDB code 4HCV) and compound 13 J in the best docking pose. (**B**) Docked complex of IL-2 receptor and torcetrapib in the best docking pose. Compound 13 J and torcetrapib were in the stick representation, whilst the amino acid residues of IL-2 receptor were displayed by solid ribbon style in the line representation. C, H, O, N and F were colored with gray, white, red, blue and brown, respectively.](1752-0509-6-152-5){#F5}

PDGFR-beta signaling pathway and the adverse effects of torcetrapib
-------------------------------------------------------------------

Platelet derived growth factor (PDGF), a 24ku cationic glycoprotein, mainly indwelt in platelet alpha granule, impaired endothelial cell, macrophages, smooth muscle cells, fibroblasts and mesangia cells, which mediated multiple interactions between tissues and endothelial cells through releasing PDGF in an autocrine and paracrine chain amplificated reaction forms \[[@B33],[@B34]\]. A variety of mechanisms involved in the development of atherosclerosis had been reported to be highly associated with PDGF. Cagnin et al. \[[@B35]\] discovered that a high level of PDGF and interleukin was detected in patients with atherosclerosis, suggesting that PDGF could influence the proceeding of atherosclerosis in association with inflammatory factors. Additionally, Cha et al. \[[@B36]\] also observed proliferation and migration in smooth muscle cell after PDGF treatment in cultured human aortic smooth muscle cells *in vitro*, which indicated that PDGF could facilitate the formation of atherosclerosis via accelerating the migration and proliferation of plaque.

Despite the fact that percutaneous coronary intervention (PCI) was one of the most effective therapeutic approaches for CHD by far, restenosis after stenting was still unavoidable, which affected the long term efficacy. Li and colleagues \[[@B37]\] disclosed that the increased expression of PDGF mRNA was found on carotid artery balloon dilatation rat. Experimental results suggested that PDGF could activate its upstream pathways via directly binding PDGFR-β, which initiated intermediate signal protein, activated mitogen activated protein kinase pathway (MAPK) cascade afterwards and promoted proliferation, migration and angiogenesis in smooth muscle cells through dimerization and autophosphorylation of tyrosine residues phosphorylated \[[@B38],[@B39]\]. Chintalgattu's research \[[@B40]\] uncovered an elevation of PDGFR-β in cardiac pressure overload mice, implicating that PDGFR-β was a compensatory reaction in heart under pressure load, which depicted the intimate relationship between the activation of PDGFR signaling pathway and cardiovascular diseases.

Owing to the availability of synthetical PDGF tyrosine kinase inhibitors, it might be conceivable to use crenolanib to exploit the binding pocket region of PDGF protein. Figure [6](#F6){ref-type="fig"} illustrated that torcetrapib perfectly matched the crystallographic position of the PDGF tyrosine kinase receptor (PDB Code 1GQ5) with 42.0439 kcal/mol by directly interacting with ARG40 and ARG80 in its besting docking pose. As is well known, H-bonds play a vital role in the stability of structure and function of biological molecules. The presence of interaction between ARG40 and ARG80 is interesting, which had been identified as the most important amino acid residue in the formation of hydrogen bond.

![**Prediction of PDGFR as a possible off-target of torcetrapib.** (**A**) Docked complex of PDGFR (PDB code 1GQ5) and crenolanib in the best docking pose. (**B**) Docked complex of PDGFR and torcetrapib in the best docking pose. Crenolanib and torcetrapib were in the stick representation, whilst the amino acid residues of PDGFR were displayed by solid ribbon style in the line representation. C, H, O, N and F were colored with gray, white, red, blue and brown, respectively.](1752-0509-6-152-6){#F6}

Aberrant ErbB pathway was associated with the off-target effects for torcetrapib
--------------------------------------------------------------------------------

Except for cancer, the ErbB family of four receptor tyrosine kinases (ErbB1, ErbB2, ErbB3 and ErbB4) also engaged in certain non-neoplastic pathologies, such as hypertension \[[@B41]\], infectious diseases \[[@B42]\] and chronic renal dysfunction \[[@B43]\]. More recent studies have demonstrated that neuregulins (NRGs)/ErbB1 signaling pathway was essential for normal myocardial development and pathological vasoconstriction, especially in cardiac smooth muscle \[[@B44]\]. One such momentous NRGs was heparin-binding (HB)-EGF. Hao et al. \[[@B41]\] reported that the activation of ErbB1 receptor mediated by HB-EGF played a significant role in cardio-vasculature and hypertension, which facilitated the formation of atherosclerotic plaque and vascular stenosis.

The three dimensional structure of ErbB1 tyrosine kinase with compound POX (4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes) was downloaded from PDB (code number 3BEL). As shown in Figure [7](#F7){ref-type="fig"}, the binding energy between torcetrapib and ErbB1 tyrosine kinase experienced a lower reduction in the best docking pose compared with compound POX (POX, 35.5674 kcal/mol; torcetrapib, 34.7466 kcal/mol). Of note, the presence of interaction in LYS913 aroused our curiosity, which was proposed as the most prominent amino acid residue in the stability of ErbB1 and POX/torcetrapib.

![**Prediction of ErbB1 tyrosine kinase as a possible off-target of torcetrapib.** (**A**) Docked complex of ErbB1 (PDB code 3BEL) and compound POX in the best docking pose. (**B**) Docked complex of ErbB1 and torcetrapib in the best docking pose. Compound POX and torcetrapib were in the stick representation, whilst the amino acid residues of ErbB1 tyrosine kinase were displayed by solid ribbon style in the line representation. C, H, O, N and F were colored with gray, white, red, blue and brown, respectively.](1752-0509-6-152-7){#F7}

HGFR pathway contributed to the unfavorable effects of torcetrapib
------------------------------------------------------------------

As a heparin binding glycoprotein originated from mesenchymal cells, hepatocyte growth factor (HGF) possessed various biological activities including regulating mitosis, morphogenesis, hematopoiesis, myocardial hypertrophy, angiogenesis, fibrosis and tissue regeneration, which were took effect via binding HGF specific receptor kinase (c-Met) \[[@B45]\]. HGF promoted mitosis and revealed anti-apoptosis effect on vascular endothelial cells. Meanwhile, there was no stimulation of HGF on the growth of smooth muscle cells, suggesting that it was a specific endothelial cell growth factor and injury repaired factor \[[@B46]\]. Previously, we found that HGF played profitable prothetic roles in the pathogenesis of CHD, especially for atherosclerosis. The autocrine or paracrine mechanisms of HGF was reduced by high concentration of transforming growth factor β (TGF-β) and AngII after endothelial damage in atherosclerosis, which resulted in the elevation of serum HGF produced by lung, liver and kidney to regulate the proliferation or migration of vascular endothelial and smooth muscle cells \[[@B47],[@B48]\].

The three dimensional crystal structure of HGF receptor and compound 03X (N-{4-\[(6,7-dimethoxyquinolin-4-yl)oxy\]-3-fluorophenyl}-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide) showed that the 6-dimethoxyquinoline and the carbonyl group in 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide could interact with the hinge region of the active site via directly coalescing with ARG1086 and ASN1171 (Figure [8](#F8){ref-type="fig"}). Similarly, a H-bond (ARG1166) adjacent to the 6-(trifluoromethyl)-1, 2, 3, 4-tetrahydroquinoline ring also contributed to the stability of torcetrapib and HGF receptor.

![**Prediction of HGFR as a possible off-target of torcetrapib.** (**A**) Docked complex of HGFR (PDB code 3UH6) and compound 03X in the best docking pose. (**B**) Docked complex of HGFR and torcetrapib in the best docking pose. Compound 03X and torcetrapib were in the stick representation, whilst the amino acid residues of HGFR were displayed by solid ribbon style in the line representation. C, H, O, N and F were colored with gray, white, red, blue and brown, respectively.](1752-0509-6-152-8){#F8}

As a CETP inhibitor, torcetrapib could activate relevant signaling pathways mentioned above through directly binding PDGFR, HGFR, IL-2 Receptor and ErbB1tyrosine kinase and up-regulating CBL, SOCS1, JAK1, JUN, TGFBR2 and EXOSC6 afterward, which subsequently exerted the exacerbation of endothelium injury and increased cardiovascular events \[[@B6]\]. Thus, a synergetic combination of anti-hypertensive drugs such as angiotensin converting enzyme inhibitors (ACEIs) was proposed to be an effective and beneficial strategy to decrease torcetrapib-associated off-target unfavorable effects in cardiovascular system \[[@B49]\].

Conclusions
===========

A whole genomic drug-gene interaction network based on the integrative manually curated signaling network and microarray profiles was established to explicate the potential off-target effects for torcetrapib. Totally, three momentous GRNs modules which might have a close relationship with the unwanted effects of torcetrapib were mined. Meanwhile, enriched analysis was carried out and certain significant enriched pathways were detected, which had been reported to have a definite correlation with cardiovascular maladjustment. In particular, we highlighted the importance of IL-2 Receptor Beta Chain in T cell Activation, PDGFR-beta signaling pathway, IL2-mediated signaling events, ErbB signaling pathway and signaling events mediated by HGFR (c-Met) and revealed that PDGFR, HGFR, IL-2 Receptor and ErbB1tyrosine kinase were direct off-targets for torcetrapib.

Taken together, these findings suggested that the network off-target effects prediction methods *in silico* were profitable for illustrating the relationship between drug and disease related off-targets for interventions. However, due to the false positive connection and noises in the reassembled network, the predictive model in this study was still far more completed. We proposed that our study on the off-target effects of torcetrapib based on network pharmacology will provide beneficial insights for further experimental validations.

Methods
=======

Microarray data analysis
------------------------

The microarray gene expression profiling associated with torcetrapib was acquired from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) database under the accession number GDS3556 \[[@B50]\]. This data set was derived from a study on H295 adrenal carcinoma cells treated with blank solvent, AngII and torcetrapib. Analysis of differently expression gene was performed by Significance Analysis of Microarray (SAM) \[[@B51]\]. If the fold change\>1.2 and False Discovery Rate (FDR)\<0.05, gene expression was considered significantly different.

Human signaling network construction
------------------------------------

To establish a comprehensive human signaling network, we manually curated the cellular signaling molecules which integrated diverse pathways resources including BioCarta, literature-mined network, Cancer Cell Map \[[@B13]\] and HPRD. An open source platform for complex network analysis and visualization named Cytoscape was freely utilized to assemble the drug-gene interaction network \[[@B14]\]. Molecular inter-relations in the integrative network were added using BisoGenet plugin from various databases including BIND, HPRD, MINT, DPI, BIOGRID and INTACT \[[@B15]\].

Functional enrichment analysis
------------------------------

Functional enrichment analysis was applied to identify primary biological processes, which provided clues to the underlying molecular mechanisms related to the adverse effects of torcetrapib. Significant clustering of genes was mined by MCODE algorithm \[[@B16]\]. All GRNs modules were classified by DAVID functional annotation tool \[[@B17],[@B18]\] to perform GO analysis on the basis of "GOTERM_BP_FAT", whilst pathway enrichment analysis was clustered by ToppFun \[[@B19]\].

Ligand preparation
------------------

Chemical structures of all ligands utilized in reverse docking protocol were generated by CambridgeSoft ChemOffice 2008. Ligands were prepared by adding charges, hydrogen and applying force field in Discovery Studio environment. Energy was also minimized with ChARMm force field before performing docking. The random conformations search of torcetrapib was conducted utilizing a high temperature simulated annealing dynamics scheme. Ligands were heated to 700 K in 2000 steps, followed by annealing to 300 K in 5000 steps. Ten random conformations were generated and a final minimization was introduced to each docking poses.

Receptor preparation
--------------------

The three dimensional structures of proteins were obtained from PDB, which contains information about experimentally-determined structures of proteins, nucleic acids and complex assemblies. Drug targets were downloaded with high resolution and without mutation or missing residues around the active site. Ligands, oligomeric chains, water molecules or solvent were spilt from proteins. All proteins were remedied through the "Prepare Protein" command in Discovery Studio protocols, which added hydrogen, fixed the missing side chains, corrected connectivity or bond orders and adjusted residue protonation states to PH 7.0.

Binding site analysis
---------------------

For binding site identification, a ligand-based approach was used for identifying the potential binding sites via "Define and Edit Binding Site" tool in Discovery Studio. Ligand-based similarity search method, a strategy utilizing compounds that are known to bind to the desired targets to identify the targets of other compounds with similar properties, is an indispensable technology that is gaining increasing usage in drug discovery. In the present study, search was performed on the global surface of the protein by similarity and substructure searching \[[@B52]\], and the automatic identification of binding sphere was considered as highly significant.

Targets prediction
------------------

A reverse docking algorithm, the opposite of a "direct" docking approach, was conducted by CDOCKER to hunt for potential targets of torcetrapib based on the enriched signaling pathways. CDOCKER, an implementation protocol in Discovery Studio environment, is a grid-based simulated annealing (several cycles) docking method through CHARMm force field docking tool \[[@B53]\]. Docking was performed using the default setting, which can avoid a potential reduction in docking accuracy.
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